Erlotinib Tablets and Zykadia
Determining the interaction of Erlotinib Tablets and Zykadia and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme. According to product labeling, coadministration with the potent CYP450 3A4 inhibitor ketoconazole increased erlotinib systemic exposure (AUC) by two-thirds compared to administration of erlotinib alone. MANAGEMENT: Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors. A dosage reduction or temporary interruption of therapy should be considered in patients who experience undue adverse effects of erlotinib such as severe diarrhea (i.e., that which is unresponsive to loperamide or results in dehydration), severe skin reactions, or severe liver function test abnormalities. References Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7 "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA.
Professional:MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme. According to product labeling, coadministration with the potent CYP450 3A4 inhibitor ketoconazole increased erlotinib systemic exposure (AUC) by two-thirds compared to administration of erlotinib alone.
MANAGEMENT: Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors. A dosage reduction or temporary interruption of therapy should be considered in patients who experience undue adverse effects of erlotinib such as severe diarrhea (i.e., that which is unresponsive to loperamide or results in dehydration), severe skin reactions, or severe liver function test abnormalities.
- Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7
- "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA.
Generic Name: erlotinib
Brand name: Tarceva
Synonyms: Erlotinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Erlotinib Tablets-Zylet
- Erlotinib Tablets-Zylet ophthalmic
- Erlotinib Tablets-Zyloprim
- Erlotinib Tablets-Zymine Liquid
- Erlotinib Tablets-Zymine-D
- Erlotinib Tablets-Zyncof
- Zykadia-Errin
- Zykadia-Ertapenem
- Zykadia-Ertapenem Injection
- Zykadia-Ertapenem Sodium
- Zykadia-Ertugliflozin
- Zykadia-Ertugliflozin and metformin